125 related articles for article (PubMed ID: 38350065)
1. 68 Ga-Pentixafor PET/CT for In Vivo Imaging of CXCR4 Receptors in Glioma Demonstrating a Potential for Response Assessment to Radiochemotherapy: Preliminary Results.
Waheed A; Singh B; Watts A; Kaur H; Singh H; Dhingra K; Ahuja C; Madan R; Singh A; Radotra BD
Clin Nucl Med; 2024 Apr; 49(4):e141-e148. PubMed ID: 38350065
[TBL] [Abstract][Full Text] [Related]
2. [
Watts A; Singh B; Singh H; Bal A; Kaur H; Dhanota N; Arora SK; Mittal BR; Behera D
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1216-1227. PubMed ID: 36482077
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the performance of
Yin X; Ai K; Luo J; Liu W; Ma X; Zhou L; Xiang X; Su X; Wang Y; Li Y
Front Endocrinol (Lausanne); 2024; 15():1291775. PubMed ID: 38419957
[TBL] [Abstract][Full Text] [Related]
4. (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.
Lapa C; Lückerath K; Kleinlein I; Monoranu CM; Linsenmann T; Kessler AF; Rudelius M; Kropf S; Buck AK; Ernestus RI; Wester HJ; Löhr M; Herrmann K
Theranostics; 2016; 6(3):428-34. PubMed ID: 26909116
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4.
Yang T; Shi D; Lin Q; Shen H; Tan H; Liu Y; Shi H; Cheng D
Mol Pharm; 2024 May; 21(5):2415-2424. PubMed ID: 38606663
[TBL] [Abstract][Full Text] [Related]
6. 68Ga-Pentixafor PET/MRI for Treatment Response Assessment in Mantle Cell Lymphoma: Comparison Between Changes in Lesion CXCR4 Expression on PET and Lesion Size and Diffusivity on MRI.
Mayerhoefer ME; Raderer M; Weber M; Lamm W; Kiesewetter B; Hacker M; Nics L; Schmitl S; Leithner D; Wester HJ; Haug A
Clin Nucl Med; 2023 Jul; 48(7):557-562. PubMed ID: 37272977
[TBL] [Abstract][Full Text] [Related]
7. Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [
Haug AR; Leisser A; Wadsak W; Mitterhauser M; Pfaff S; Kropf S; Wester HJ; Hacker M; Hartenbach M; Kiesewetter-Wiederkehr B; Raderer M; Mayerhoefer ME
Theranostics; 2019; 9(12):3653-3658. PubMed ID: 31281504
[TBL] [Abstract][Full Text] [Related]
8. Chemokine Receptor 4-Targeted PET/CT With 68 Ga-Pentixather Detects More Lesions Than 68 Ga-Pentixafor PET/CT in Multiple Myeloma.
Yang Q; Zhang F; Hao Z; Zhuang J; Huo L
Clin Nucl Med; 2024 Jun; 49(6):592-593. PubMed ID: 38630995
[TBL] [Abstract][Full Text] [Related]
9. CXCR4-Directed PET/CT with [
Chen Z; Yang A; Zhang J; Chen A; Zhang Y; Huang C; Chen S; Yao S; Miao W
Mol Imaging Biol; 2022 Jun; 24(3):416-424. PubMed ID: 34651291
[TBL] [Abstract][Full Text] [Related]
10. CXCR4-Directed Imaging in Solid Tumors.
Werner RA; Kircher S; Higuchi T; Kircher M; Schirbel A; Wester HJ; Buck AK; Pomper MG; Rowe SP; Lapa C
Front Oncol; 2019; 9():770. PubMed ID: 31475113
[TBL] [Abstract][Full Text] [Related]
11. Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [
Kosmala A; Duell J; Schneid S; Serfling SE; Higuchi T; Weich A; Lapa C; Hartrampf PE; Raderer M; Einsele H; Buck AK; Topp MS; Schlötelburg W; Werner RA
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):749-755. PubMed ID: 37943339
[TBL] [Abstract][Full Text] [Related]
12.
Watts A; Singh B; Singh H; Kaur H; Bal A; Vohra M; Arora SK; Behera D
J Nucl Med Technol; 2022 Sep; 50(3):278-281. PubMed ID: 35610039
[No Abstract] [Full Text] [Related]
13. The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism.
Zheng Y; Long T; Peng N; Zhen M; Ye Q; Zhang Z; He Y; Chen Z; Gan Y; Luo M; Li C; Liu Z; Guo M; Wang M; Luo X; Hu S; Liu L; Jiang T
J Clin Endocrinol Metab; 2023 Dec; 109(1):171-182. PubMed ID: 37477496
[TBL] [Abstract][Full Text] [Related]
14. Functional nodules in primary aldosteronism: identification of CXCR4 expression with
Gao Y; Ding J; Cui Y; Li T; Sun H; Zhao D; Zhang Y; Huo L; Tong A
Eur Radiol; 2023 Feb; 33(2):996-1003. PubMed ID: 36070092
[TBL] [Abstract][Full Text] [Related]
15. Imaging CXCR4 receptors expression for staging multiple myeloma by using
Shekhawat AS; Singh B; Malhotra P; Watts A; Basher R; Kaur H; Hooda M; Radotra BD
Br J Radiol; 2022 Aug; 95(1136):20211272. PubMed ID: 35731811
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI.
Starzer AM; Berghoff AS; Traub-Weidinger T; Haug AR; Widhalm G; Hacker M; Rausch I; Preusser M; Mayerhoefer ME
Clin Nucl Med; 2021 Jan; 46(1):16-20. PubMed ID: 33208624
[TBL] [Abstract][Full Text] [Related]
17. [
Li X; Yu W; Wollenweber T; Lu X; Wei Y; Beitzke D; Wadsak W; Kropf S; Wester HJ; Haug AR; Zhang X; Hacker M
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1616-1625. PubMed ID: 31004184
[TBL] [Abstract][Full Text] [Related]
18. Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT.
Pan Q; Cao X; Luo Y; Li J; Li F
Clin Nucl Med; 2021 Sep; 46(9):732-737. PubMed ID: 34172595
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of chemokine receptor 4 expression in chronic osteomyelitis confirms specific uptake in 68Ga-Pentixafor-PET/CT.
Bouter Y; Meller B; Sahlmann CO; Wolf BJ; Langer L; Bankstahl JP; Wester HJ; Kropf S; Meller J; Bouter C
Nuklearmedizin; 2018 Sep; 57(5):198-203. PubMed ID: 30267402
[TBL] [Abstract][Full Text] [Related]
20. Chemokine receptor-4 targeted PET/CT with
Pan Q; Cao X; Luo Y; Li J; Feng J; Li F
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):537-546. PubMed ID: 31776631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
